Catapult’s news – Standing out: Defining the market for your new ATMP asset

Academic teams are very good at generating proof of concept (PoC) data to illustrate the potential of their nascent cell or gene therapy. However, when raising investment from venture capital (VC) firms, PoC data is only a part of what is required. Even brilliant new technology will often struggle to raise investment unless the commercial potential can be described.

In this blog, Sam Goldsmith, Head of Commercialisation of Research and Investments at the Cell and Gene Therapy Catapult, highlights why and how academics should develop a coherent narrative describing their novel therapy’s unmet need in the market, and how their proposition will differentiate from both current and emerging competitors.

This is the third in a series of blogs to help academic leaders identify and focus on key considerations when seeking investment to commercialise their advanced therapy concepts.

Published on the 27th of March 2024. Read the entire news report here.